Novo Nordisk is embroiled in "pay-for-delay" agreement allegations regarding Victoza

Novo Nordisk has been taken to court in a U.S. federal court, accused of monopolizing the Victoza drug market by entering into illegal agreements with Teva Pharmaceutical Industries Ltd. (an Israeli company) to delay the launch of generic drugs. J M Smith alleges that Novo Nordisk bribed Teva to postpone the launch of its Victoza generic drug until June 2024 and is seeking to initiate a class action lawsuit on behalf of direct purchasers. The lawsuit also claims that Novo Nordisk manipulated regulatory processes to prevent the U.S. Food and Drug Administration (FDA) from approving any potential competitors for Victoza and seeks relief under Section 2 of the Sherman Act